Fight the Urge to Sell: 3 Stocks With Terrible Charts That Still Look Like Buying Opportunities If You’re Patient Enough

I recently saw a social media post which stood out to me. This post was a long-term chart going back about 50 years, highlighting all the downturns over this time frame, and all the reasons investors had to sell at particular down points in the market. 

There were so many near-term downturns (which now look like extremely minor blips on the radar) which must have been downright frightening at the time. But over the long-term, even the most protracted declines didn’t turn out to be much more than near-term volatility, with the stock market taking the stairs higher eventually and making a new all-time high. 

The saying that stocks take the stairs up, and the elevator down, is definitely true. But for those playing the long game, these near-term dips have always proven to be buying opportunities. The difficult piece is having the mental fortitude to stick it out through the rough times, and ride the long-term earnings growth power of corporate America to new all-time highs at some point in the future.

For those who hope to exemplify the patience of Warren Buffett and other truly long-term investors, here are three ugly charts I think may be worth stepping into right now. 

Curaleaf (CURLF)

The cannabis sector is one that has had the cream kicked out of it over the course of the past five years or so. Following a number of surges tied to Canadian legalization of cannabis in late-2018 and the pandemic, with investors looking for anything that could have parabolic upside, companies like Curaleaf (OTCMKTS:CURLF) has absolutely crashed.

Down more than 66% all-time, this is a stock with a chart that most investors want to look away from, particularly when zooming out.

Now, the dynamics for Curaleaf and other U.S. multi-state operators in the cannabis industry has changed dramatically in recent months. The Trump administration has signaled it will be reclassifying marijuana as a less-dangerous drug, opening up cannabis for medical research to start. Many in the sector believe this is a first step toward legalization, though it’s unlikely we’ll see such legalization take hold under a Republican administration. Of course, given the unpredictable nature of this administration, I’m not going to rule that out – I’m just talking about probabilities right now.

The thing is, Curaleaf’s market share in its core markets through the U.S. is meaningful. I think the company’s vertically integrated business model, its potential for profitability without federal legalization, and the longer-term catalyst that legalization in the U.S. could bring, make for a fantastic buying opportunity for those who can wait. 

There’s always the potential this sector could get hit by more headwinds down the line. But I’m of the view that most of the downside in companies like Curaleaf has likely already been priced in. Thus, CURLF stock is a strong buy in my books on this recent decline. 

iShares Bitcoin Trust ETF (IBIT)

The iShares Bitcoin Trust ETF (IBIT) is a top exchange traded fund option for investors looking for exposure to the price of Bitcoin. This ETF is designed to mirror the price moves of Bitcoin on a daily basis, and as such, has a chart that is essentially identical to that of any on-chain chart tracking Bitcoin’s price.

The thing is, spot ETFs weren’t broadly approved until 2024, and IBIT came into existence in January of that year. So, we’re only working with roughly two years of data here, and there’s been plenty of upside for investors who bought this ETF at its outset.

That said, since this ETF’s all-time high in late-2025, shares of IBIT are down nearly 30% from their peak. For those who think Bitcoin is a long-term buying opportunity, this decline is notable and one worth considering. 

I’m not saying Bitcoin will rally tomorrow and hit new all-time highs this year. But on the balance of probabilities (historically speaking), that’s what’s happened. 

So, for those with a long investing time horizon and a higher tolerance for risk, the iShares Bitcoin Trust ETF may be worth considering here. 

Lululemon (LULU)

Retail stocks haven’t performed very well at all in recent years. Indeed, 2025 was a significant down year for a number of top players in this space, with Lululemon (NASDAQ:LULU) perhaps the most prescient example of how a highly-valued quality retailer can see its valuation decline materially in short order.

In 2025, shares of LULU stock lost more than 40% of their value, and this trend appears poised to continue into 2026. That kind of decline has prompted some talk among Chip Wilson (the company’s former CEO) and other leading shareholders to change the company’s leadership and potentially force other key decisions to turn this ship around.

The thing is, I still see Lululemon’s brand as one of the best in the marketplace. The company’s cash on hand, relative lack of debt, and ability to scale its business model (particularly into new markets in Asia and around the world clamoring for this brand) is impressive. The question of course is whether this tariff regime, and belt-tightening among consumers across the income spectrum, may drive much slower growth in the years ahead.

In my view, this nearly 45% decline has factored in these risks, and then some. Now trading at a valuation of just 16-times earnings with a better balance sheet profile than most retailers, LULU stock looks like a screaming buy to me.